A Phase 1, Open-Label, Food Effect, And Dose Proportionality Study With Omaveloxolone In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Omaveloxolone (Primary)
- Indications Friedreich's ataxia; Malignant melanoma; Mitochondrial disorders; Non-small cell lung cancer; Ocular inflammation; Ocular pain
- Focus Pharmacokinetics
- Sponsors Reata Pharmaceuticals
- 27 Aug 2019 Status changed from recruiting to completed.
- 12 Nov 2018 Status changed from not yet recruiting to recruiting.
- 17 Sep 2018 New trial record